Physician profile
Michael Williamson
NPI 1730703562
$753.25
in general payments reported to CMS, 2019-2025
14 companies · $65.43 in 2025
The $65.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $212 · 2024: $357 · 2025: $65.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.56 | 2023-2025 | Vraylar |
| Medtronic, INC. | $145.45 | 2022-2025 | Inceptiv, Intellis Adaptivestim |
| Corium, LLC | $88.95 | 2023-2025 | Azstarys |
| Lilly USA, LLC | $88.02 | 2023-2024 | Mounjaro, Trulicity, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.02 | 2023-2024 | Xifaxan |
| Pfizer INC. | $35.64 | 2024 | |
| Dexcom, INC. | $25.74 | 2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $20.70 | 2024 | Heplisav-B |
| Ultragenyx Pharmaceutical INC. | $18.27 | 2022 | |
| Merck Sharp & Dohme LLC | $17.45 | 2023 | Vaxneuvance, Varivax, M-M-R II |
| Mayne Pharma Commercial LLC | $17.07 | 2023 | |
| Idorsia Pharmaceuticals US INC | $14.56 | 2024 | Quviviq |
| Glaxosmithkline, LLC. | $14.13 | 2023 | Trelegy Ellipta |
| Seqirus USA INC | $13.69 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.